TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 11535508

Group type: EXPERIMENTAL
Intervention: FLT3/ITD mutation present
Number of subjects: 854

Group type: EXPERIMENTAL
Intervention: Presence of a mutation
Number of subjects: 854

Group type: EXPERIMENTAL
Intervention: More than one mutation in FLT3/ITD(+) patients
Number of subjects: 854

Group type: EXPERIMENTAL
Intervention: Biallelic disease or partial/complete loss of wild-type alleles in FLT3/ITD(+) patients
Number of subjects: 854
Study: 9759983

Group type: EXPERIMENTAL
Intervention: Losartan 50 mg
Number of subjects: 77

Group type: COMPARATOR
Intervention: Hydrochlorothiazide 25 mg
Number of subjects: 77
Study: 7826829

Group type: EXPERIMENTAL
Intervention: gamma-L-glutamyl-5-hydroxy-L-tryptophan (glu-5-HTP)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: carbidopa (100 mg)
Number of subjects: 8

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 8
Study: 2595518

Group type: EXPERIMENTAL
Intervention: Structured educational intervention
Number of subjects: 340

Group type: COMPARATOR
Intervention: Standard information according to the clinic protocol
Number of subjects: 340
Study: 1038614

Group type: EXPERIMENTAL
Intervention: Toothbrush at four-hour intervals
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Toothbrush at two-hour intervals
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Toothette
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Toothbrush
Number of subjects: 48
Study: 31449675

Group type: EXPERIMENTAL
Intervention: Exposure to the school personnel workshop
Number of subjects: 488

Group type: EXPERIMENTAL
Intervention: Exposure to the student curriculum
Number of subjects: 488

Group type: EXPERIMENTAL
Intervention: Exposure to the handout
Number of subjects: 488

Group type: EXPERIMENTAL
Intervention: Higher baseline knowledge and reactive bystander intentions
Number of subjects: 488

Group type: EXPERIMENTAL
Intervention: Fewer barriers to bystander action
Number of subjects: 488

Group type: EXPERIMENTAL
Intervention: Combination of intervention components
Number of subjects: 488

Group type: COMPARATOR
Intervention: No intervention components
Number of subjects: 488
Study: 30741579

Group type: EXPERIMENTAL
Intervention: Rapid maxillary expansion (RME) using Haas/Hyrax expander
Number of subjects: 46

Group type: COMPARATOR
Intervention: Slow maxillary expansion (SME) using quad-helix appliance
Number of subjects: 46
Study: 28662034

Group type: COMPARATOR
Intervention: MA (20 mg Sb+5/kg/day for 20 days)
Number of subjects: 378

Group type: EXPERIMENTAL
Intervention: LAMB (3 mg/kg/day for 7 days)
Number of subjects: 378

Group type: EXPERIMENTAL
Intervention: LAMB plus MA (10 mg/kg single dose plus 20 mg Sb+5/kg/day for 10 days)
Number of subjects: 378

Group type: EXPERIMENTAL
Intervention: AmphoB (1 mg/kg/day for 14 days)
Number of subjects: 378

Group type: EXPERIMENTAL
Intervention: LAMB
Number of subjects: 378
Study: 25628286

Group type: EXPERIMENTAL
Intervention: Open carpal tunnel release with subneural reconstruction of the transverse carpal ligament (n = 68)
Number of subjects: 213

Group type: COMPARATOR
Intervention: Isolated open carpal tunnel release (n = 92)
Number of subjects: 213

Group type: COMPARATOR
Intervention: Endoscopic carpal tunnel release (n = 53)
Number of subjects: 213
Study: 22551835

Group type: EXPERIMENTAL
Intervention: Lifestyle modification program
Number of subjects: 0
Study: 20514956

Group type: EXPERIMENTAL
Intervention: Midazolam and morphine (group M)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Ondansetron and morphine (group O)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Morphine alone (group C)
Number of subjects: 90
Study: 18541571

Group type: EXPERIMENTAL
Intervention: Selenium supplements (200 mug as selenomethionine)
Number of subjects: 913

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 913
Study: 15780456

Group type: EXPERIMENTAL
Intervention: Transformed visual feedback (inverted in both vertical and horizontal axes)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Transformed visual feedback (inverted along a single axis as in a mirror‐inversion)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Baseline condition (no visual feedback transformation)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Adaptation to visual feedback
Number of subjects: 0
Study: 12482332

Group type: EXPERIMENTAL
Intervention: Combination chemotherapy including irinotecan, oxaliplatin, and 5-fluorouracil (5-FU) with leucovorin
Number of subjects: 0

Group type: COMPARATOR
Intervention: 5-FU-based regimens alone
Number of subjects: 0
Study: 10549700

Group type: EXPERIMENTAL
Intervention: Pulsed Electromagnetic Fields (PEMF)
Number of subjects: 195

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 195

Group type: EXPERIMENTAL
Intervention: Long-term follow-up
Number of subjects: 195
Study: 7728786

Group type: EXPERIMENTAL
Intervention: Oral milrinone 2.5 mg
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Oral milrinone 5 mg
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Oral milrinone 10 mg
Number of subjects: 31
Study: 2340612

Group type: EXPERIMENTAL
Intervention: Caudal block with 0.5 ml.kg‐1 of bupivacaine 0.25% following induction of anaesthesia before surgery
Number of subjects: 40

Group type: COMPARATOR
Intervention: Caudal block at the completion of surgery before emergence from general anaesthesia
Number of subjects: 40
Study: 7182948

Group type: EXPERIMENTAL
Intervention: Oral administration of butropium bromide (BB) at doses of 10 and 15 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Intramuscular administration of butropium bromide (BB) at doses of 0.25 and 0.5 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Intramuscular administration of butropium bromide (BB) at doses of 0.25-2.0 mg/person
Number of subjects: 0
Study: 30590716

Group type: EXPERIMENTAL
Intervention: ACEi/ARBs
Number of subjects: 13741

Group type: EXPERIMENTAL
Intervention: β-blockers
Number of subjects: 13741

Group type: EXPERIMENTAL
Intervention: ACEi/ARBs + β-blockers
Number of subjects: 13741

Group type: COMPARATOR
Intervention: Matched controls without antihypertensive treatment
Number of subjects: 13741
Study: 28189123

Group type: EXPERIMENTAL
Intervention: Cyproterone acetate (CPA) 10 mg/20 mg
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Levonorgestrel (LNG) 120 μg/240 μg
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Norethisterone acetate (NETA) 5 mg/10 mg
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Nestorone® (NES) 2 mg/3 mg
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Transdermal testosterone (T)
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Combination of progestins with transdermal testosterone
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: All groups (CPA, LNG, NETA, NES)
Number of subjects: 56
Study: 26472098

Group type: EXPERIMENTAL
Intervention: Azelaic acid
Number of subjects: 32

Group type: COMPARATOR
Intervention: Combined oral contraceptive
Number of subjects: 32
Study: 23378537

Group type: EXPERIMENTAL
Intervention: Standard therapy with educational materials (EMs)
Number of subjects: 4844

Group type: COMPARATOR
Intervention: Standard therapy
Number of subjects: 4844
Study: 21088596

Group type: EXPERIMENTAL
Intervention: Protective OLV with tidal volume 6 ml/kg, FIO2 of 0.5, PEEP of 5 cmH2O
Number of subjects: 49

Group type: COMPARATOR
Intervention: Conventional OLV with tidal volume 10 ml/kg, FIO2 of 1.0, no PEEP
Number of subjects: 49
Study: 19552728

Group type: EXPERIMENTAL
Intervention: Ibandronate 6 mg intravenous every 4 weeks for 24 months
Number of subjects: 150

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Ibandronate
Number of subjects: 150
Study: 17325898

Group type: EXPERIMENTAL
Intervention: P-VEBEC
Number of subjects: 232

Group type: COMPARATOR
Intervention: Mini-CEOP
Number of subjects: 232
Study: 16448299

Group type: EXPERIMENTAL
Intervention: Contextual factors (physicians' ages, race-ethnicities, patient race-ethnicity, office-related barriers)
Number of subjects: 235

Group type: EXPERIMENTAL
Intervention: Theoretical predictors from the theory of planned behavior, social-cognitive theory, and the transtheoretical model
Number of subjects: 235
Study: 12900686

Group type: EXPERIMENTAL
Intervention: Carbohydrate (CHO) ingestion (6.4%, 64 g x L‐1)
Number of subjects: 9

Group type: COMPARATOR
Intervention: Placebo (PLA) beverage ingestion
Number of subjects: 9
Study: 10870740

Group type: EXPERIMENTAL
Intervention: Older generation antidepressants (e.g., amitriptyline, nortriptyline)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Anticonvulsant (e.g., gabapentin)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Chronic opioid therapy
Number of subjects: 0
Study: 9014776

Group type: EXPERIMENTAL
Intervention: Oxytocin 20 mU/min
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Oxytocin 30 mU/min
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Oxytocin 50 mU/min
Number of subjects: 26

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 26
Study: 1643195

Group type: EXPERIMENTAL
Intervention: Diazepam 5 mg/70 kg
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Diazepam 10 mg/70 kg
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Diazepam (5 or 10 mg/70 kg)
Number of subjects: 6

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6
Study: 6487547

Group type: EXPERIMENTAL
Intervention: Minutes' therapy with dithranol in Lassar's paste
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Short-contact therapy with dithranol in Lassar's paste
Number of subjects: 33

Group type: COMPARATOR
Intervention: Standard Ingram regime of 24-hour application
Number of subjects: 33
Study: 31389333

Group type: EXPERIMENTAL
Intervention: COPe-support (Carers fOr People with Psychosis e‐support) eHealth intervention
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: COPe-support eHealth intervention
Number of subjects: 38
Study: 29493524

Group type: EXPERIMENTAL
Intervention: Intramedullary nailing (IMN)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Minimally invasive percutaneous plate osteosynthesis (MIPPO)
Number of subjects: 60
Study: 25245226

Group type: EXPERIMENTAL
Intervention: Lactobacillus reuteri
Number of subjects: 300

Group type: COMPARATOR
Intervention: Nystatin
Number of subjects: 300
Study: 23286422

Group type: EXPERIMENTAL
Intervention: Caffeine (6 mg x kg(‐1))
Number of subjects: 14

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study: 21730779

Group type: EXPERIMENTAL
Intervention: Amoxicillin-clavulanic acid combination treatment for 10 days after abscess drainage
Number of subjects: 183

Group type: COMPARATOR
Intervention: Placebo treatment for 10 days after abscess drainage
Number of subjects: 183
Study: 19074638

Group type: EXPERIMENTAL
Intervention: Full-fat exposure (10 s)
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Nonfat exposure (10 s)
Number of subjects: 34

Group type: COMPARATOR
Intervention: No oral exposure (10 s)
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Full-fat exposure (20 min)
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Nonfat exposure (20 min)
Number of subjects: 34
Study: 17122238

Group type: EXPERIMENTAL
Intervention: General anesthesia combined with epidural analgesia (EDA group)
Number of subjects: 16

Group type: COMPARATOR
Intervention: General anesthesia with desflurane (control group)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Both groups (EDA and control)
Number of subjects: 16
Study: 15589853

Group type: EXPERIMENTAL
Intervention: Recombinant LH in addition to increased dose of FSH (group B)
Number of subjects: 128

Group type: EXPERIMENTAL
Intervention: Increased dosage of FSH (group A)
Number of subjects: 128

Group type: EXPERIMENTAL
Intervention: Additional FSH and LH using hMG (group C)
Number of subjects: 128

Group type: COMPARATOR
Intervention: Control group (D) with no need to increase FSH dose
Number of subjects: 128
Study: 11510063

Group type: EXPERIMENTAL
Intervention: Patient-controlled epidural analgesia (PCEA) with bupivacaine and fentanyl
Number of subjects: 0

Group type: COMPARATOR
Intervention: Continuous epidural mepivacaine
Number of subjects: 0
Study: 9425484

Group type: EXPERIMENTAL
Intervention: Guillotine tonsillectomy
Number of subjects: 64

Group type: COMPARATOR
Intervention: Dissection tonsillectomy
Number of subjects: 64
Study: 8502522

Group type: EXPERIMENTAL
Intervention: Oral penicillin V
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: Intramuscular benzathine penicillin G
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: Oral erythromycin estolate
Number of subjects: 47

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 47
Study: 3098425

Group type: EXPERIMENTAL
Intervention: Rioprostil 300 micrograms
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Rioprostil 150 micrograms
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 28094559

Group type: EXPERIMENTAL
Intervention: Fotonovela condition (translated into Dutch)
Number of subjects: 202

Group type: EXPERIMENTAL
Intervention: Traditional brochure condition (in Dutch)
Number of subjects: 202

Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 202

Group type: EXPERIMENTAL
Intervention: Fotonovela condition
Number of subjects: 202

Group type: EXPERIMENTAL
Intervention: Traditional brochure condition
Number of subjects: 202
Study: 28934191

Group type: EXPERIMENTAL
Intervention: 12-week individualised aerobic exercise programme (n=29)
Number of subjects: 53

Group type: COMPARATOR
Intervention: 12-week waiting control group (n=24)
Number of subjects: 53
Study: 25269680

Group type: EXPERIMENTAL
Intervention: Home-based pulmonary rehabilitation program
Number of subjects: 29

Group type: COMPARATOR
Intervention: Control group (telephone call without guidance on exercise)
Number of subjects: 29
Study: 23137292

Group type: EXPERIMENTAL
Intervention: EndoVac (chemomechanical debridement with EndoVac system)
Number of subjects: 125

Group type: EXPERIMENTAL
Intervention: PDT (chemomechanical debridement with conventional irrigation and PDT)
Number of subjects: 125

Group type: EXPERIMENTAL
Intervention: EndoVac+PDT (chemomechanical debridement with EndoVac and PDT)
Number of subjects: 125

Group type: COMPARATOR
Intervention: Control (chemomechanical debridement with conventional irrigation)
Number of subjects: 125
Study: 21621394

Group type: EXPERIMENTAL
Intervention: 4:1 ketogenic ratio diet
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: 2.5:1 ketogenic ratio diet
Number of subjects: 38
Study: 18646266

Group type: EXPERIMENTAL
Intervention: Cluster randomized cross-over design
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Sample size formula for continuous outcomes
Number of subjects: 0
Study: 16958775

Group type: EXPERIMENTAL
Intervention: Nurse practitioner management (NURS) including individualized lifestyle modification and pharmacologic intervention for 1 year after discharge
Number of subjects: 228

Group type: COMPARATOR
Intervention: Usual care (EUC) enhanced with feedback on lipids to their primary provider and/or cardiologist
Number of subjects: 228
Study: 14665353

Group type: EXPERIMENTAL
Intervention: Tamsulosin (0.4 mg daily) for 30 days before biopsy
Number of subjects: 66

Group type: COMPARATOR
Intervention: Control group (no tamsulosin treatment)
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Tamsulosin group
Number of subjects: 66

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 66
Study: 12823087

Group type: EXPERIMENTAL
Intervention: Interferon alfa-2b therapy (5 million units 3 times per week or 3 to 5 million units 3 times per week with ribavirin 1000-1200 mg/day)
Number of subjects: 104

Group type: EXPERIMENTAL
Intervention: Interferon alfa-2b therapy
Number of subjects: 104

Group type: COMPARATOR
Intervention: Untreated reference group
Number of subjects: 104
Study: 10827325

Group type: EXPERIMENTAL
Intervention: Computer-based trauma simulator
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Seminar-based teaching
Number of subjects: 100

Group type: COMPARATOR
Intervention: Comparison group (no additional teaching)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Computer-based trauma simulator and Seminar-based teaching
Number of subjects: 100
Study: 8892128

Group type: EXPERIMENTAL
Intervention: Discharge planning and 8-week home follow-up provided by advanced practice nurses, including home visits, telephone outreach, and daily telephone availability.
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: Home visits (more than two required for more than half of the women), mean home visit time was 1 hour.
Number of subjects: 61
Study: 2059530

Group type: EXPERIMENTAL
Intervention: Double-headed toothbrush (Duodent 2000)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Conventional toothbrush (Oral B 32)
Number of subjects: 50
Study: 6334974

Group type: EXPERIMENTAL
Intervention: Mechanical vibratory stimulation at 100 Hz applied directly to the pruritic area
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Mechanical vibratory stimulation at 10 Hz and 200 Hz
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Transcutaneous electrical nerve stimulation (TENS) at 2 Hz and 100 Hz
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo conditioning procedure
Number of subjects: 12
Study: 29768364

Group type: EXPERIMENTAL
Intervention: Fragility fracture integrated rehabilitation management (FIRM)
Number of subjects: 282

Group type: COMPARATOR
Intervention: Conventional rehabilitation
Number of subjects: 282

Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 282
Study: 26979312

Group type: EXPERIMENTAL
Intervention: T-DM1 3.6 mg/kg every three weeks or 2.4 mg/kg weekly + paclitaxel 80 mg/m2 weekly ± pertuzumab 840 mg loading dose followed by 420 mg q3w
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: T-DM1 + paclitaxel ± pertuzumab
Number of subjects: 44
Study: 24660647

Group type: EXPERIMENTAL
Intervention: Red laser therapy (4 J/cm2 in temporomandibular joints and 8 J/cm2 in muscles, three sessions)
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Infrared laser therapy (4 J/cm2 in temporomandibular joints and 8 J/cm2 in muscles, three sessions)
Number of subjects: 19
Study: 21593809

Group type: EXPERIMENTAL
Intervention: Selenium supplementation (200 µg sodium selenite/day for 3 weeks)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo control
Number of subjects: 10
Study: 20504899

Group type: EXPERIMENTAL
Intervention: Mixed insulins (insulin detemir mixed with aspart)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Separate insulins (insulin detemir and aspart given separately)
Number of subjects: 14
Study: 17631952

Group type: EXPERIMENTAL
Intervention: Omalizumab + Ragweed immunotherapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Ragweed immunotherapy alone
Number of subjects: 0
Study: 15625202

Group type: EXPERIMENTAL
Intervention: Mixed amphetamine salts
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30

Group type: COMPARATOR
Intervention: Divalproex sodium
Number of subjects: 30
Study: 12394374

Group type: EXPERIMENTAL
Intervention: Formula with long chain polyunsaturated fatty acids (F+LCP)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Formula without long chain polyunsaturated fatty acids (F)
Number of subjects: 40
Study: 9706918

Group type: COMPARATOR
Intervention: Clonidine 5 microg/kg p.o. (Group C)
Number of subjects: 35

Group type: COMPARATOR
Intervention: Lorazepam 60 microg/kg p.o. (Group L)
Number of subjects: 35

Group type: COMPARATOR
Intervention: Morphine 0.1 mg/kg plus scopolamine 6 microg/kg i.m. (Group M)
Number of subjects: 35
Study: 8907407

Group type: EXPERIMENTAL
Intervention: DWI prevention program (videotape, slides, textbook, manual)
Number of subjects: 208

Group type: COMPARATOR
Intervention: Traditional curriculum (control group)
Number of subjects: 208
Study: 2403593

Group type: EXPERIMENTAL
Intervention: Selection of a drug by the capillary cloning system
Number of subjects: 133

Group type: COMPARATOR
Intervention: Selection of a drug by the clinician
Number of subjects: 133

Group type: EXPERIMENTAL
Intervention: Overall response rate for all patients
Number of subjects: 133

Group type: EXPERIMENTAL
Intervention: Overall survival rates
Number of subjects: 133
Study: 76798

Group type: EXPERIMENTAL
Intervention: Transfer factor from random normal donors
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 16
Study: 30476931

Group type: EXPERIMENTAL
Intervention: Foster care intervention
Number of subjects: 0

Group type: COMPARATOR
Intervention: Never-institutionalized
Number of subjects: 0
Study: 29071967

Group type: EXPERIMENTAL
Intervention: Modified acupuncture at Renying point (ST 9)
Number of subjects: 59

Group type: COMPARATOR
Intervention: Routine acupuncture technique
Number of subjects: 59
Study: 26164120

Group type: EXPERIMENTAL
Intervention: Implementation intentions intervention (participants listed what fruits and vegetables they would eat and when and where they would eat them)
Number of subjects: 108

Group type: COMPARATOR
Intervention: Control condition (participants did not list fruits and vegetables)
Number of subjects: 108

Group type: EXPERIMENTAL
Intervention: Implementation intentions intervention (replicated in Experiment 2)
Number of subjects: 108
Study: 23200303

Group type: EXPERIMENTAL
Intervention: Atomoxetine (80 mg/day; p.o.)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study: 21656068

Group type: EXPERIMENTAL
Intervention: CO(2) insufflation
Number of subjects: 80

Group type: COMPARATOR
Intervention: Air insufflation
Number of subjects: 80
Study: 18754988

Group type: EXPERIMENTAL
Intervention: Nurse-delivered telephone intervention for smoking cessation
Number of subjects: 50

Group type: COMPARATOR
Intervention: Control group (nonabused women)
Number of subjects: 50
Study: 16423200

Group type: EXPERIMENTAL
Intervention: Asthmatic pregnant women
Number of subjects: 50
Study: 12603366

Group type: EXPERIMENTAL
Intervention: Behçet's Disease patients
Number of subjects: 27

Group type: COMPARATOR
Intervention: Control subjects
Number of subjects: 27
Study: 11337976

Group type: EXPERIMENTAL
Intervention: CLA supplementation (3.9 g/d)
Number of subjects: 17

Group type: COMPARATOR
Intervention: Sunflower oil (control group)
Number of subjects: 17
Study: 9152654

Group type: EXPERIMENTAL
Intervention: Class I (presence of vital exhaustion)
Number of subjects: 2449

Group type: EXPERIMENTAL
Intervention: Class II (no vital exhaustion, depression, low levels of anxiety)
Number of subjects: 2449

Group type: EXPERIMENTAL
Intervention: Type A behaviour among patients eligible for exercise test
Number of subjects: 2449

Group type: EXPERIMENTAL
Intervention: High levels of neuroticism and extroversion
Number of subjects: 2449

Group type: EXPERIMENTAL
Intervention: Clinical variables (exercise test ineligibility, late and early ventricular failure)
Number of subjects: 2449
Study: 7515651

Group type: EXPERIMENTAL
Intervention: CHVmP-VB
Number of subjects: 346

Group type: COMPARATOR
Intervention: ProMACE-MOPP
Number of subjects: 346